Tags » Transparency

Incretin mimetics: liraglutide (Victoza) unpublished studies (ClinicalTrials.gov, EudraCT, and UMIN) → 69%

AllTrials

Jorge Ramírez reblogged this on Chaos Theory and Human Pharmacology and commented:

I. Background

Unpublished and published liraglutide studies in humans - Completed before Jan 2011 Unpublished (n=37): 68.5% Published (n=17): 31.5% ----> 3.1 papers per registry

35 out of 39 ClinicalTrials.gov registers were retrospectively registered Median = - 250 days Q1 = - 2128 days Q3 = -18 days


"In the Novo Nordisk study, the rats treated with liraglutide showed increased ductal proliferation and acinar to ductal metaplasia. One rat treated with exenatide had a “hemorrhagic pancreas” at necropsy with 'moderate apoptosis-like necrosis, minimal inflammatory infiltration and slight hemorrhage/edema.”13Although the pancreases did not increase in weight, the incretin treated rats had “significantly higher” levels of pancreatic amylase. Three of the liraglutide treated animals died from a 'single erroneous dosing.' A spokeswoman from Novo Nordisk told the BMJ, 'Importantly, the study did not find any abnormalities in the pancreas associated with liraglutide treatment."--- Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013; 346.

 
"Science thrives on open challenge and objective debate. Patients will not receive safe and effective care in an environment characterised by commercial secrecy, bullying of academics and journal editors, or reliance on overstretched regulators." --- Goodle F. Secrecy does not serve us well. 2013;346:f3819

 
"In the point narrative below, Dr. Butler and colleagues provide their opinion and review of the data to date and that we need to reconsider the use of incretin-based therapies because of the growing concern of potential risk and based on a clearer understanding of the mechanism of action. In the counterpoint narrative following the contribution by Dr. Butler and colleagues, Dr. Nauck provides a defense of incretin-based therapies and that the benefits clearly outweigh any concern of risk." --- Butler and colleagues. A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care. 2013 Jul;36(7):2118-25.

 II. ClinicalTrials.gov study results: NCT00318461

(1) "Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Restriction Description: Novo Nordisk acknowledges the Investigator’s right to publish the entire results of the trial. Any such scientific paper, presentation, communication or other information concerning the investigation described in this protocol, must be submitted in writing to Novo Nordisk Trial Manager prior to submission for publication/presentation for comments. Comments will be given within four weeks from receipt of the manuscript."

(2) Secondary outcome: change in bodyweight

Baseline values for weight are not reported (only for BMI)

(3) Race: limited external validity

Race (NIH/OMB) [units: participants] American Indian or Alaska Native 0 Asian 98 Native Hawaiian or Other Pacific Islander 0 Black or African American 26 White 946 More than one race 0 Unknown or Not Reported 17
Jamaluddin JL, et al. Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes. Pharmacogenomics. 2014 Feb;15(2):235-49. doi: 10.2217/pgs.13.234. Abstract "In the adult pancreas, the expression of the genes PAX4, KCNQ1, TCF7L2, KCNJ11, ABCC8, MTNR1B and WFS1 are mainly restricted to β cells to maintain glucose homeostasis. We have identified these genes as the main regulators of incretin-mediated actions, and therefore they may potentially influence the response of DPP-4 inhibitors. This review represents the first detailed exploration of pancreatic β-cell genes and their variant mechanisms, which could potentially affect the response of DPP-4 inhibitors in Type 2 diabetes. We have focused on the signaling pathways of these genes to understand their roles in gastrointestinal incretin-mediated effects; and finally, we sought to associate gene mechanisms with their Type 2 diabetes risk variants to predict the responses of DPP-4 inhibitors for this disease."

(4) Metformin monotherapy study arm (sample size) vs. other study arms (sample size) = 1:2

(5) Change in beta-cell function

  • Week 26: statistical significant differences only with liraglutide groups compared with metformin monotherapy.
  • Week 104: no statistically significant differences among the study groups.

(6) History of changes: No significant changes were detected in the study


Acknowledgments

Lorena Hoyos -- undergraduate medical student at the University of Valle --- for reminding me about incretin mimetics.
To be continued...

(What's Left of) Our Economy: A Flat Earth-ist Argument for TPP

I don’t know what it is about international economic and trade policy that turns otherwise intelligent people into the professional equivalent of morons, but it urgently needs intensive study. 309 more words

{What's Left Of) Our Economy

US allies fear Obama admin leaking information to Iran

Hotair

Just how badly has Barack Obama and his administration damaged relations with our allies in the Middle East? NBC’s Richard Engel reports that the Sunni nations in the region have begun to fear that the Obama administration leaks intel to Iran as part of its efforts at 

232 more words
Politics

Saying "No" Not an Option for Some High Achievers: Ask Madeleine

Dear Madeleine,

I’ve been with a small and very successful business for fifteen years and am a senior manager. Every time we want to try something new, I am asked to be in charge of it—even though I already have a full-time job and am running all the other initiatives and programs I’ve successfully started for the company. 603 more words

Behavior Change

Monitoring Officer - some questions

Should a Monitoring Officer also be a council’s Legal Officer?

Mr Gordon Lennox is currently EDDC’s Principal Solicitor and appears to have had enough work to keep him fully busy in the job for some years. 250 more words

EDDC

Don't Look Now, but Hillary Clinton's E-Mail Scandal Just Got a Whole Lot Worse

I know, I know. You didn’t think it was possible for Hillary Clinton’s e-mail scandal to get any worse. And yet, here we are: 410 more words

Caged Bird, Free Spirit

Disclaimer: This may come off as venting and for that I apologize… carry on.

It’s funny when we want something so much that we swear if we had it life would be better yet somehow when opportunities arise to get what we want we don’t jump at it. 856 more words

Lifelessons